Investors

Home / Investors / Financials
v3.23.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 59,150 $ 20,291
Marketable securities 177,215 115,194
Prepaid expenses and other current assets 6,355 2,588
Total current assets 242,720 138,073
Property and equipment, net 729 701
Operating lease right-of-use asset 137 169
Other assets 1,733 2,909
Total assets 245,319 141,852
Current liabilities:    
Accounts payable 1,633 1,096
Accrued research and development expenses 5,565 6,530
Deferred collaboration revenue 33,733 0
Other accrued liabilities 5,569 7,815
Total current liabilities 46,500 15,441
Development financing liability 94,630 90,227
Long-term portion of operating lease liability 0 30
Total liabilities 141,130 105,698
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 200,000,000 shares authorized; 97,330,560 and 84,681,063 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 17 8
Additional paid-in capital 1,005,877 909,329
Accumulated other comprehensive loss (70) (326)
Accumulated deficit (901,635) (872,857)
Total stockholders' equity 104,189 36,154
Total liabilities and stockholders' equity $ 245,319 $ 141,852
v3.23.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 18,551 $ 18,415
General and administrative 8,324 6,087
Total operating expenses 26,875 24,502
Loss from operations (26,875) (24,502)
Other income (expense), net:    
Interest income 2,013 98
Interest expense (4,403) (3,365)
Other income 487 0
Total other income (expense), net (1,903) (3,267)
Net loss (28,778) (27,769)
Other comprehensive loss:    
Unrealized gain (loss) on marketable securities, net of tax 256 (206)
Total other comprehensive loss 256 (206)
Comprehensive loss $ (28,522) $ (27,975)
Basic net loss per common share $ (0.29) $ (0.32)
Diluted net loss per common share $ (0.29) $ (0.32)
Weighted average common shares outstanding used to calculate basic net loss per common share 97,971,081 87,802,939
Weighted average common shares outstanding used to calculate diluted net loss per common share 97,971,081 87,802,939
v3.23.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities    
Net loss $ (28,778) $ (27,769)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 199 169
Stock-based compensation expense 3,487 2,414
Accretion of development financing liability 4,403 3,365
Net accretion and amortization of investments in marketable securities (1,318) 131
Changes in assets and liabilities:    
Prepaid expenses and other current assets (3,767) 1,077
Other assets 1,176 (728)
Accounts payable 537 (2,341)
Deferred collaboration revenue 33,733 0
Accrued research and development expenses (965) (93)
Other accrued liabilities (2,276) (1,587)
Net cash provided by (used in) operating activities 6,431 (25,362)
Investing activities    
Purchases of property and equipment (195) 0
Purchases of marketable securities (121,097) (62,485)
Proceeds from maturities of marketable securities 60,650 11,495
Net cash (used in) investing activities (60,642) (50,990)
Financing activities    
Proceeds from issuance of common stock pursuant to equity award plans 710 0
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs 92,360 (459)
Proceeds from development financing 0 25,000
Net cash provided by financing activities 93,070 24,541
Net increase (decrease) in cash and cash equivalents 38,859 (51,811)
Cash and cash equivalents at beginning of period 20,291 125,806
Cash and cash equivalents at end of period 59,150 73,995
Supplemental disclosure    
Cash paid for amounts included in the measurement of lease liabilities $ 176 $ 171